"Recurrence" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The return of a sign, symptom, or disease after a remission.
| Descriptor ID |
D012008
|
| MeSH Number(s) |
C23.550.291.937
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recurrence".
Below are MeSH descriptors whose meaning is more specific than "Recurrence".
This graph shows the total number of publications written about "Recurrence" by people in this website by year, and whether "Recurrence" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 18 | 18 |
| 1996 | 0 | 13 | 13 |
| 1997 | 0 | 17 | 17 |
| 1998 | 0 | 21 | 21 |
| 1999 | 0 | 16 | 16 |
| 2000 | 0 | 12 | 12 |
| 2001 | 0 | 15 | 15 |
| 2002 | 0 | 21 | 21 |
| 2003 | 0 | 24 | 24 |
| 2004 | 0 | 27 | 27 |
| 2005 | 0 | 18 | 18 |
| 2006 | 0 | 33 | 33 |
| 2007 | 0 | 29 | 29 |
| 2008 | 0 | 33 | 33 |
| 2009 | 0 | 26 | 26 |
| 2010 | 0 | 38 | 38 |
| 2011 | 0 | 39 | 39 |
| 2012 | 0 | 25 | 25 |
| 2013 | 0 | 46 | 46 |
| 2014 | 0 | 36 | 36 |
| 2015 | 0 | 38 | 38 |
| 2016 | 0 | 40 | 40 |
| 2017 | 0 | 41 | 41 |
| 2018 | 0 | 51 | 51 |
| 2019 | 0 | 47 | 47 |
| 2020 | 0 | 42 | 42 |
| 2021 | 0 | 38 | 38 |
| 2022 | 0 | 26 | 26 |
| 2023 | 0 | 26 | 26 |
| 2024 | 9 | 12 | 21 |
| 2025 | 0 | 7 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recurrence" by people in Profiles.
-
Percutaneous transluminal angioplasty and stenting (PTAS) in patients with symptomatic intracranial vertebrobasilar artery stenosis (IVBS). Stroke Vasc Neurol. 2025 Apr 29; 10(2).
-
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025 Mar 25; 9(6):1356-1365.
-
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241.
-
Core domain set for chronic and/or recurrent manifestations of calcium pyrophosphate deposition disease: OMERACT delphi survey to establish consensus. Semin Arthritis Rheum. 2025 Jun; 72:152669.
-
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025 Feb 25; 9(4):696-703.
-
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after =2 prior therapies. Blood. 2025 Feb 13; 145(7):708-719.
-
Association Between Sun Exposure and Risk of Relapse in Pediatric-Onset Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Mar; 12(2):e200375.
-
Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis. Neurology. 2025 Feb 25; 104(4):e210213.
-
Treatment of rapid recurrence of severe steatosis with combined glucagon-like peptide-1 agonist and growth hormone therapy in a pediatric patient transplanted for metabolic dysfunction-associated steatohepatitis cirrhosis in the setting of hypopituitarism. Am J Transplant. 2025 May; 25(5):1123-1126.
-
Co-Occurrence of ETV6::RUNX1 and P2RY8::CRLF2 Fusion in a Patient with Relapsed Acute B Lymphoblastic Leukemia. Ann Clin Lab Sci. 2025 Jan; 55(1):133-141.